Breakthrough in cancer research: New therapy shows success at LMD!
Breakthrough in cancer research: New therapy shows success at LMD!
Wien, Österreich - The leptomeningeal metastatic disease (LMD) represents a serious complication in advanced solid tumors, especially for breast and lung cancer. This disease often leads to a rapid progression of the disease and usually has fatal consequences because the treatment options are limited. An international research team led by MedUni Vienna and the AKH Vienna recently tested a promising therapy based on the active ingredient Patritumab Deruxtecan (Her3-DXD). This is reported by the OTS
The results of this study were presented at the annual conference of the American Society of Clinical Oncology (ASCO) in Chicago and have also been published in the renowned journal "Nature Medicine". In the Tuxedo-3 study, 20 patients received: Inside with untreated LMD at seven clinics in Austria and Spain, the antibody-active ingredient conjugate Her3-DXD, which specifically binds to the Her3 receptor on tumor cells and insert a cell poison into the cancer cell.
gratifying results and improved quality of life
After three months of treatment, 65 % of the subject survived: inside, which was above the expectations of the researchers. The quality of life of most patients also remained stable on the inside or improved, which indicates the potential of therapy. LMD occurs in up to 10 % of the patient: on the inside with advanced solid tumors. Symptoms include headaches, nausea and neurological failures.
Without treatment, life expectancy is often only a few weeks, while with the new therapy in individual cases, an extension is possible to several months. Her3-DXD not only shows promising clinical effectiveness and acceptable tolerance at LMD, but is also researched in patients: inside with metastases in the brain. The goal is to develop new treatment options for these clinical pictures that are difficult to treat.
The context of cancer research
The global health threat of cancer is alarming. Every year, almost three million people are diagnosed with cancer in the EU, with around 10 million people die from this disease worldwide in 2025. These figures could take almost unacceptable dimensions by 2050, especially with regard to the increasing life expectancy. Therefore, an increased need for innovation in cancer research is determined. Progress in oncology have led to the discovery of new medication, such as BTK inhibitors, while targeted therapies and antibody-active ingredient conjugate (ADCS) are increasingly in focus. This is pointed out Handelsblatt Hin.
The challenges of clinical development should also not be underestimated, since about 75 % of the costs are eliminated to carry out clinical studies. With companies such as bees, which is involved in the global planning and care of clinical studies, development times for therapies could reduce up to 30 %. In times when new therapy approaches are urgently needed, sustainable framework conditions and transparent communication between all involved are essential so that advanced therapies such as HER3-DXD can soon be used.
| Details | |
|---|---|
| Ort | Wien, Österreich |
| Quellen | |